Email this article RECOMBINANT ANTIGENS OF PSEUDOMONAS AERUGINOSA: EFFECT ON IMMUNE RESPONSE IN MICE
- Authors: Mikhaylova N.A.1, Kalinichenko E.O.1, Soldatenkova A.V.1, Akhmatova N.K.1
-
Affiliations:
- Mechnikov Research Institute of Vaccines and Sera
- Issue: Vol 94, No 3 (2017)
- Pages: 52-58
- Section: ORIGINAL RESEARCHES
- Submitted: 10.04.2019
- Published: 28.06.2017
- URL: https://microbiol.crie.ru/jour/article/view/160
- DOI: https://doi.org/10.36233/0372-9311-2017-3-52-58
- ID: 160
Cite item
Full Text
Abstract
Aim. Study the effect of recombinant antigens of P. aeruginosa on key effectors of the immune system. Materials and methods. Mice were immunized intraperiotoneally with 25 jig of OprF and 50 jig of anatoxin sorbed on aluminium hydroxide gel with a 2 week interval. 7 days after the last immunization spleen lymphocyte subpopulation structure was evaluated by flow cytometry. Cytokine levels in mice sera were studied after a single immunization with recombinant OprF and anatoxin at 4, 8, 24 hours and 14 days by flow cytometry using FlowCytomix Mouse Thl/Th2 10 plex. Results. OprF recombinant antigens and anatoxin affect molecular-cell mechanisms of immune response resulting in alteration of expression of differentiating and activating molecules as well as synthesis of Thl/Th2/Thl7/Th21/Th22 cytokines in mice that are necessary for effective presentation of the antigen. Conclusion. Complex of recombinant OprF and anatoxin facilitated formation of complete immune response against pseudomonas.
About the authors
N. A. Mikhaylova
Mechnikov Research Institute of Vaccines and Sera
Author for correspondence.
Email: noemail@neicon.ru
Россия
E. O. Kalinichenko
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Россия
A. V. Soldatenkova
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Россия
N. K. Akhmatova
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Россия
References
- Калошин А.А., Гатыпова Е.В., Михайлова Н.А. Получение рекомбинантных форм белка F наружной мембраны Pseudomonas aeruginosa и исследование их иммуногенных свойств. Биотехнология. 2011, 2: 74-84.
- Калошин А.А., Леонова Е.И., Солдатенкова А.В., Михайлова Н.А. Исследование протективных свойств комплекса рекомбинантного белка F наружной мембраны и рекомбинантного анатоксина Pseudomonas aeruginosa. Вестник РАМН. 2016, 71 (1): 117-122.
- Калошин А.А., Исаков М.А., Михайлова Н.А., Вертиев Ю.В. Получение рекомбинантной атоксической формы экзотоксина A Pseudomonas aeruginosa. Бюллетень экспериментальной биологии и медицины. 2012, 9: 330-335.
- Лазарева А.В., Чеботарь И.В., Крыжановская О.А., Чеботарь В.И., Маянский Н.А. Pseudomonas aeruginosa: патогенность, патогенез и патология. Клиническая микробиология и антимикробная химиотерапия. 2015, 17 (3): 170-186.
- Baumann U., Mansouri Е., von Specht B.U. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine. 2004, 22 (7): 840-847.
- Doring G., Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 2008,26(8): 1011-1024.
- Edwards-Jones V, Greenwood J.E. What’s new in bum microbiology? James Laing Memorial Prize Essay 2000. Burns. 2003, 29: 15-24.
- Hasan M., Neumann B., Haupeltshofer S. et al. Activation of TGF-fMnduced non-Smad signaling pathways during Thl7 differentiation. Immunology Cell. Biology. 2015, 3: 216-223.
- Hertle R., Mrsny R., Fitzgerald D.J. Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein. Barbieri J.T. (ed.). Infection Immunity. 2001, 69 (11): 6962-6969.
- Lund-Palau H., Turnbull A.R., Bush A. et al. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev. Respiratory Medicine. 2016, 10 (6): 685-697.
- Pier G.B., Ramphal R. Pseudomonas aeruginosa. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. New York, 2010.
- Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clinical Investigation. 2002, 109 (3): 317-325.
Supplementary files
